Clinical, Dermoscopic and Microscopic Features of a “Collision Tumour” Ultimately Confirmed as a Regressing Melanoma – Lessons Learnt from a Chance Diagnosis

References

• Sumner WC. Spontaneous regression of melanoma. Report of a case. Cancer. 1953;6(5):1040–1043. doi:10.1002/1097-0142(195309)6:5<1040::aid-cncr2820060525>3.0.co;2-5
   PubMed Web of Science ®Google Scholar
• Gardner LJ, Strunck JL, Wu YP, Grossman D. Current controversies in early-stage melanoma: questions on incidence, screening, and histologic regression. J Am Acad Dermatol. 2019;80(1):1–12. doi:10.1016/j.jaad.2018.03.053
   PubMed Web of Science ®Google Scholar
• Ribero S, Moscarella E, Ferrara G, Piana S, Argenziano G, Longo C. Regression in cutaneous melanoma: a comprehensive review from diagnosis to prognosis. J Eur Acad Dermatol Venereol. 2016;30:2030–2037. doi:10.1111/jdv.13815
   PubMed Web of Science ®Google Scholar
• Moscarella E, Bombonato C, Pampena R, et al. Pigmented skin lesions displaying regression features: dermoscopy and reflectance confocal microscopy criteria for diagnosis. Exp Dermatol. 2019;28(2):129–135. doi:10.1111/exd.13853
   PubMed Web of Science ®Google Scholar
• Moretti S, Spallanzani A, Pinzi C, Prignano F, Fabbri P. Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment? J Cutan Pathol. 2007;34(4):301–308. doi:10.1111/j.1600-0560.2006.00616.x
   PubMed Web of Science ®Google Scholar
• Niculet E, Craescu M, Rebegea L, et al. Basal cell carcinoma: comprehensive clinical and histopathological aspects, novel imaging tools and therapeutic approaches (Review). Exp Ther Med. 2022;23(1):60. doi:10.3892/etm.2021.10982
   PubMed Web of Science ®Google Scholar
• Carrera C, Segura S, Aguilera P, et al. Dermoscopic clues for diagnosing melanomas that resemble Seborrheic Keratosis. JAMA Dermatol. 2017;153(6):544–551. doi:10.1001/jamadermatol.2017.0129
   PubMed Web of Science ®Google Scholar
• Kurzeja M, Czuwara J, Walecka I, Olszewska M, Rudnicka L. Features of classic lichen planopilaris and frontal fibrosing alopecia in reflectance confocal microscopy: a preliminary study. Skin Res Technol. 2021;27(2):266–271. doi:10.1111/srt.12940
   PubMed Web of Science ®Google Scholar
• Nwabudike LC, Tatu AL, Gambichler T, et al. Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery. J Eur Acad Dermatol Venereol. 2019;33(1):e3–e4. doi:10.1111/jdv.15084
   PubMed Web of Science ®Google Scholar
• Tatu AL, Ciobotaru OR, Miulescu M, et al. Hydrochlorothiazide: chemical structure, therapeutic, phototoxic and carcinogenetic effects in dermatology. Rev Chim. 2018;69(8):2110–2114. doi:10.37358/RC.18.8.6484
   Web of Science ®Google Scholar
• Tatu AL, Elisei AM, Chioncel V, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin (review). Exp Ther Med. 2019;18:955–959. doi:10.3892/etm.2019.7504
   PubMed Web of Science ®Google Scholar
• Nwabudike LC, Elisei AM, Buzia OD, Miulescu M, AL Tatu. A review on structural perspectives, adverse reactions and relations with non-melanoma skin cancer. Rev Chim. 2018;69(9):2557–2562. doi:10.37358/RC.18.9.6575
   Web of Science ®Google Scholar
• Cui J, Bystryn JC. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol. 1995;131:314–318. doi:10.1001/archderm.1995.01690150078015
   PubMedGoogle Scholar
• Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer. 1994;30:1209–1211. doi:10.1016/0959-8049(94)90493-6
   Web of Science ®Google Scholar
• Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19(15):3477–3482. doi:10.1200/JCO.2001.19.15.3477
   PubMed Web of Science ®Google Scholar
• Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology. 1992;20(4):315–322. doi:10.1111/j.1365-2559.1992.tb00988.x
   PubMed Web of Science ®Google Scholar
• High WA, Stewart D, Wilbers CRH, Cockerell CJ, Hoang MP, Fitzpatrick JE. Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J Am Acad Dermatol. 2005;53(1):89–100. doi:10.1016/j.jaad.2005.03.006
   PubMed Web of Science ®Google Scholar
• Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–1123. doi:10.1677/ERC-09-0087
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer M. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685. doi:10.2337/dc10-0666
   PubMed Web of Science ®Google Scholar
• Wojciechowska J, Krajewski W, Bolanowski M, Krecicki T, Zatonski T. Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016;124(5):263–275. doi:10.1055/s-0042-100910
   PubMed Web of Science ®Google Scholar
• Simo R, Plana-Ripoll O, Puente D. Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PLoS One. 2013;8(11):e79968. doi:10.1371/journal.pone.0079968
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–1777. doi:10.1007/s00125-009-1440-6
   PubMed Web of Science ®Google Scholar
• Dzwierzynski WW. Managing malignant melanoma. Plast Reconst Surg. 2013;132(3):446e–460e. doi:10.1097/PRS.0b013e31829ad411
   PubMed Web of Science ®Google Scholar
• Enomoto LM, Levine EA, Shen P, Votanopoulos KI. Role of surgery for metastatic melanoma. Surg Clin North Am. 2019;100:127–139.
   PubMed Web of Science ®Google Scholar
• Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther. 2017;7(Suppl 1):5–19. doi:10.1007/s13555-016-0165-y
   PubMed Web of Science ®Google Scholar
• Avril MF, Charpentier P, Margulis A, Guillaume JC. Regression of primary melanoma with metastases. Cancer. 1992;69(6):1377–1381. doi:10.1002/1097-0142(19920315)69:6<1377::AID-CNCR2820690613>3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Arpaia N, Cassano N, Vena GA. Regressing cutaneous malignant melanoma and vitiligo-like depigmentation. Int J Dermatol. 2006;45(8):952–956. doi:10.1111/j.1365-4632.2004.02468.x
   PubMed Web of Science ®Google Scholar